Nick Manusos News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Kenai Therapeutics a biotechnology company leveraging induced pluripotent stem cell iPSC technology to discover and develop a platform of allogeneic neuron replacement cell therapies for neurological disorders today announced an 82 million Series A financing coled by Alaska Permanent Fund Corporation Cure Ventures and The Column Group with participation from Euclidean Capital and Saisei Ventures.

Ryne Biotechnology has received a $4m CLIN1 grant from the California Institute for Regenerative Medicine (CIRM) to advance its lead candidate RNDP-001.

San Diego-based Ryne Biotechnology, a company developing stem cell technology to treat neurological disorders, says it has received a $4M grant from the California Institute for Regenerative Medicine (CIR

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases News provided by Share this article FUJIFILM CAMBRIDGE, Mass., and MADISON, Wis., May 17, 2021 /PRNewswire/ -- BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, FUJIFILM Cellular Dynamics, Inc. a leading global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, and Opsis Therapeutics, LLC, a joint venture of FUJIFILM Cellular Dynamics...